Sanofi (France)
NEWS
With its acquisition, Sanofi aims to establish a firm toehold in the mRNA space by integrating dedicated research and development capabilities, chemistry, manufacturing and controls.
Topline results from a late-stage trial show Regeneron Pharmaceuticals and Sanofi’s Dupixent reduced itch in biologic-naiïve patients with chronic spontaneous urticaria.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The trial is the third study in a set of pivotal trials to report positive data for the therapy.
Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer.
It was another busy week for clinical trial announcement. Here’s a look.
Sanofi’s troubles stemming from the 2019 recall of Zantac appear to be far from over.
May is a busy month for the U.S. Food and Drug Administration (FDA)’s calendar for new drug reviews. Here’s a look.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
JOBS
IN THE PRESS